指南与共识肿瘤 PET/CT

卢加诺分类在霍奇金和非霍奇金淋巴瘤初始评估、分期和疗效评估中的应用:PRoLoG共识倡议(第一部分-临床)

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).
指南 / 共识 · J Nucl Med · 2022-07-14

该共识由PINTaD的PRoLoG工作组通过2019年7月至2021年9月系列会议制定,针对卢加诺分类在淋巴瘤初始评估、分期和疗效评估中的不一致与模糊之处给出推荐,澄清PET/CT与诊断CT技术考虑、5分法4分和5分及X类别、代谢与解剖反应组合、骨髓评估及脾肝测量等,作为2014版卢加诺分类的配套指南。

要点

  • 共识澄清了不同淋巴瘤实体的FDG亲和性、反应命名及病灶分类和评分。
  • 特别细化了5分法中4分、5分及X类别的判定。
  • 明确了代谢与解剖反应组合及不一致或缺失评估时的反应评估。

核心结论

  • 共识推荐全面处理终端用户在疗效评估中遇到的分类不一致和模糊之处,应作为2014版卢加诺分类的配套指南使用。

研究设计与样本

  • 由学术和行业淋巴瘤与影像专家组成的联盟通过2019年7月至2021年9月系列会议获得共识,由PINTaD赞助,作为PRoLoG共识倡议的一部分。

主要发现

  • 共识推荐澄清了卢加诺分类中PET/CT和诊断CT的技术考虑,包括更新不同淋巴瘤实体的FDG亲和性、澄清反应命名、细化病灶分类和评分,尤其涉及5分法的4分、5分及X类别。
  • 澄清了代谢与解剖反应的组合,以及不一致或缺失评估时的反应评估。
  • 根据淋巴瘤实体进一步更新了分类中临床数据的使用,尤其是骨髓评估的要求。
  • 对脾和肝的测量与评估以及淋巴结反应提供了澄清。

关键数值与推荐

  • 共识推荐更新了不同淋巴瘤实体的FDG亲和性。
  • 共识推荐细化5分法中4分、5分及X类别的病灶分类和评分。
  • 共识推荐根据淋巴瘤实体更新骨髓评估要求。
  • 共识推荐澄清脾和肝测量与评估及淋巴结反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for consistent application of the Lugano classification. Methods: Consensus was obtained through a series of meetings from July 2019 until September 2021 sponsored by the Pharma Imaging Network for Therapeutics and Diagnostics (PINTaD) as part of the PINTaD Response Criteria in Lymphoma Working Group (PRoLoG) consensus initiative. Results: Consensus recommendations clarified technical considerations for PET/CT and diagnostic CT from the Lugano classification, including updating the FDG avidity of different lymphoma entities, clarifying the response nomenclature, and refining lesion classification and scoring, especially with regard to scores 4 and 5 and the X category of the 5-point scale. Combination of metabolic and anatomic responses is clarified, as well as response assessment in cases of discordant or missing evaluations. Use of clinical data in the classification, especially the requirement for bone marrow assessment, is further updated on the basis of lymphoma entities. Clarification is provided with regard to spleen and liver measurements and evaluation, as well as nodal response. Conclusion: Consensus recommendations are made to comprehensively address areas of inconsistency and ambiguity in the classification encountered during response evaluation by end users, and such guidance should be used as a companion to the 2014 Lugano classification.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ricard F, Cheson B, Barrington S, et al. Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical). J Nucl Med. 2022. PMID: 35835580. doi:10.2967/jnumed.122.264106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。